Details for Patent: 9,044,480

Which drugs does patent 9,044,480 protect, and when does it expire?

Patent 9,044,480 protects VIEKIRA XR, TECHNIVIE, and VIEKIRA PAK (COPACKAGED), and is included in three NDAs.

Summary for Patent: 9,044,480

Title:	Compositions and methods for treating HCV
Abstract:	The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.
Inventor(s):	Pilot-Matias; Tami (Green Oaks, IL), Gaultier; Isabelle A. (Libertyville, IL), Tripathi; Rakesh L. (Palatine, IL), Collins; Christine A. (Skokie, IL), Cohen; Daniel E. (Highland Park, IL), Bernstein; Barry M. (Mequon, WI)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	13/412,167
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,044,480

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No						TREATMENT OF HCV INFECTION USING PARITAPREVIR
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No						TREATMENT OF HCV INFECTION USING PARITAPREVIR
Abbvie	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium; ombitasvir, paritaprevir, ritonavir	TABLET;ORAL	206619-001	Dec 19, 2014		DISCN	Yes	No						TREATMENT OF HCV INFECTION USING PARITAPREVIR